Sign In
Buy BAYRY
$9.92
+0.0400 (+0.405%)
At Close: Jun 03, 2026
Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer
05:05am, Tuesday, 08'th Oct 2024
Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.
5 Large Drug Stocks to Watch From a Thriving Industry
11:00am, Monday, 07'th Oct 2024
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are wo
Bayer Reports Positive Safety Data on Parkinson's Disease Drug
03:50pm, Monday, 30'th Sep 2024
BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.
MustGrow Biologics CEO discusses commercial expansion, Bayer partnership - ICYMI
09:41am, Saturday, 28'th Sep 2024
MustGrow Biologics Corp. (TSX-V:MGRO, OTCQB:MGROF) CEO Corey Giasson joined Proactive to chat about the company's transition to commercialization from its R&D focus. He noted the commercialization of
Bayer Submits Application for Label Expansion of Prostate Cancer Drug
11:20am, Friday, 27'th Sep 2024
BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
10:41am, Thursday, 26'th Sep 2024
Pfizer, Eli Lilly, AstraZeneca, Bayer and Sanofi can prove to be great additions to your portfolio.
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the submission of a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the oral androgen receptor inhibi
ORION CORPORATION INVESTOR NEWS 26 SEPTEMBER 2024 at 11.00 EEST Orion's collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has beco
Bayer (BAYRY) Moves to Buy: Rationale Behind the Upgrade
01:05pm, Wednesday, 25'th Sep 2024
Bayer (BAYRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PITTSBURGH--(BUSINESS WIRE)--Bayer, UPMC Magee-Womens Hospital and Pennsylvania State Senator Kim Ward (R-Westmoreland County) are collaborating to address the health access gaps that disproportionall
Bayer Reports Encouraging NSCLC Drug Data, Gets Approval for Eylea 8mg
10:06am, Tuesday, 10'th Sep 2024
BAYRY's NSCLC drug BAY 2927088 shows an encouraging safety profile in the expansion part of the ongoing study. The company also announces the approval of Eylea 8mg.
Bayer: Speculative Value Beyond Litigation Pressures
01:13am, Saturday, 07'th Sep 2024
Bayer's Q2 2024 results were mixed, with strong Pharmaceuticals performance offsetting challenges in Crop Science and stable Consumer Health results. The reaffirmation of full-year guidance and a sign
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
10:21am, Monday, 02'nd Sep 2024
BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
Bayer Initiates Late-Stage Study on Investigational NSCLC Drug
02:36pm, Friday, 30'th Aug 2024
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
Bayer, NextRNA to Develop Therapeutics Targeting Oncology
10:20am, Thursday, 29'th Aug 2024
BAYRY collaborates with NextRNA Therapeutics to develop small molecule therapeutics targeting lncRNAs in oncology.
